GSE171045
Effects of androgen receptor degradation by PROTAC ARCC-32 on gene expression in LN95 prostate cancer cells
RNA-seq was performed in duplicate on LN95 prostate cancer cells at 16, 24, and 48 hours after degrdation of full length androgen recpetor by ARCC-32 Overall design: LN95 prostate cancer cells, which express both full length androgen receptor (AR-FL) and the V7 splice variant (AR-V7) were cultured in steroid depelted medium. They were then treated with a PROTAC (ARCC-32) that selectively degrades AR-FL, and assessed for gene expression in duplicate after 16, 24, or 48 hours versus vehicle control treated cells.